Acute Myeloid Leukemia in Surin hospital
Article Sidebar
Main Article Content
Abstract
Background: Untreated acute myeloid leukemia (AML) is universally fatal. In the past few years, there were many cases of AML patients receiving treatment at Surin hospital. Therefore, we have initiated to study the characteristics, treatment and outcome of AML patients in our hospital.
Objectives: To study the characteristic including age, sex, FAB classification, cytogenetics, complete remission (CR) achievement after the induction course in AML patients.
Setting: Surin hospital
Study design: Descriptive retrospective study.
Method: A retrospective reviewed of 21 newly diagnosed AML patients receiving treatment at Surin hospital during 1 January 2006 - 31 December 2008. The demographic data, age, sex, FAB classification, cytogenetics, CR achievement after the induction course were analyzed.
Results: Among 21 patients, 10 males (47.6%) and 11 females (53.4%), age ranges between 15-60 years (mean 41.95 years), In cytogenetics groups, patients with favorable, intermediate and unfavorable cytogenetics were 9.5%, 71.4%, and 19.1% respectively. Regarding FAB classification, majority of the patients were Ml (28.5%) follow by M2, M3, M4, M0, M5, M6 and M7 with the percentages of 14.3%, 14.3%, 14.3%, 9.5%, 9.5%, 4.8% and 4.8% respectively. The outcome of the treatment was classified based on CR. The percentages of the patients with CR, not CR and death were 66.6%, 19.0% and 14.3% respectively.
Complete remission in AML patients in Surin hospital was 66.6% and mortality rate was 14.3%, all patients died of infectious
Conclusion: complication after treatment. Strictly infectious control was very important in these patients to decreased mortality rate.
Key words: Acute Myeloid Leukemia, AML, cytogenetics, complete remission, cytosine arabinoside, anthracycline
Article Details
References
Silverberg E, Lubera JA. Cancer statisties. CA 1989; 39:3-20.
Champlin R Gale RP. Acute myelogenous leukaemia : recent advances in therapy. Blood 1987;69:1551-62.
Stein RS. Review : Advances in therapy of acute nonlymphogenic leukaemia. Am J Med Sci 1989; 297:26-34.
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemia (FAB co-operative group). Br J Hematol 1976;33:451-8.
Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for classification of acute myeloid leukemia. Ann totem Med 1985;103:620-9.
Lowenberg B, Downing JR Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-62.
Giles FJ, Keating A, Goldstone AH, Avivi I, Willman CL, Kantarjian HM. Acute myeloid leukemia. In : Hematology 2002. Washington, DC: American Society of Hematology 2002: 73-110.
Slovak ML, Kopecky KJ, Cassileth PA. et aL Karyotypic analysis predicts outcome of preremission and postremission therapy in acute myeloid leukemia: a Southwest Oncology Group/Eastern Oncology Group study. Blood 2000;96:4075-83.
Mrozek K, Heinonen K, dela Cahapelle A, Bloomfield CD. Clinical Significance of Cytogenetics in Acute Myeloid Leukemia. Seminars in Oncology 1997;24: 17-31.
Grimwade D., Walker H, Oliver F. et al. The Important of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into The MRC AML 10 Trail. Blood 1998:92: 2322-33.
Cheryl LW. Molecular Evaluation of Acute Myeloid Leukemia. Seminars in Hematology 1999;36: 390-400.
Grier HE, Gelber RD, Camitta BM, et al. Prognostic Factor in Childhood Acute Myeloid Luekemia. Journal of Clinical Oncology 1987;5:1026-32.
Delmer B, Jean-Pierre M Danielle T. et al. Multivariate Analysis of Prognostic Factors in Acute "Myeloid Leukemia.: Value of Clonogenic Leukemia Cell Properties. Journal of Clinical Oncology 1998;7:738-46.
Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of surviving in de novo acute myeloid leukemia. British Journal of Haematology 2000;111:196-203.
Byrd JC, Mrozek K, Dorge RK, et al. Pre-treatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
Bishop JF, Matthews JP, Young GA, et al. A Randomized Study of High-Dose Cytarabine in Induction in Acute Myeloid Luekemia. Blood 1996;87:1710-7.
Yate JW, Glidewell O, Wiemik PH, et al. Cytosine Arabinoside With Daunorubicin or Adriamycin for Therapy of Acute Myelocytic Leukemia : A CALGB Study! Blood 1982;60:454-62.
Archimbaud E, Jehn U, Thomas X, et al. Multicenter randomized phase n trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/ consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia. Leukemia 1999;13:843-9.
Vogler WR Velez-Garcia E, Wliner RS, et al. A phase in trial comparing idarubicin and daunorubicin in acute myelogenous leukaemia : a Southern Cancer Study Group studys. J Clin Oncol 1992;10:1103-11.
Wiemik PH, Banks PLC, Case PC Jr. et al. Cytarabine plus Idarubicin or Daunorubicin as Induction and Consolidation Therapy for Previously Untreated Adult Patients With Acute Myeloid Leukemia. Blood 1992;79:313-9.
Arlin Z, Case DC J. Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 1990;4:177-83.
Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus Daunorubicin in Induction-Consolidation Chemotherapy-The Value of Low-Dose Cyarabine for Maintenance of Remission, and an Assessment of Prognostic Factors in Acute Myeloid Leukemia in the Elderly : Final Report of the Leukemia Cooperative Group of the European Organnization for the Reseach and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group Randomized Phase III Study AML-9. Journal of clinical Oncology 1998;16:872-81.
Giamarellou H, Antoniadou A. Infectious complications of febrile leukopenia. Infect Dis Clinics of N. Am. 2001;15:457-82.
Donowitz GR, Maki DG, Cmich CJ, et al. Infections in the Neutropenic Patient-New Views of an Old Problem. In : Hematology 2001. Washington, DC: American Society of Hematology 2001:113-39.
ชุษณะ สวนกระต่าย. ภาวะไข้และเม็ดเลือดขาวต่ำ. ใน : พรรณทิพย์ ฉายากุล, ชิษณุ พันธุ์เจริญ และคณะ, บรรณาธิการ. ตำราโรคติดเชื้อ. กรุงเทพฯ : โฮลิสติก ; 2548 : 1008-73.
